Abstract
Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Current Pharmaceutical Biotechnology
Title:Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Volume: 17 Issue: 7
Author(s): Radzislaw Mierzynski, Dominik Dluski, Dorota Darmochwal-Kolarz, Elzbieta Poniedziałek-Czajkowska, Bozena Leszczynska-Gorzelak, Zaneta Kimber-Trojnar, Agnieszka-Wankowicz and Jan Oleszczuk
Affiliation:
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Abstract: Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Export Options
About this article
Cite this article as:
Mierzynski Radzislaw, Dluski Dominik, Darmochwal-Kolarz Dorota, Poniedziałek-Czajkowska Elzbieta, Leszczynska-Gorzelak Bozena, Kimber-Trojnar Zaneta, Agnieszka-Wankowicz and Oleszczuk Jan, Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders, Current Pharmaceutical Biotechnology 2016; 17 (7) . https://dx.doi.org/10.2174/1389201017666160301104323
DOI https://dx.doi.org/10.2174/1389201017666160301104323 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins
Current Pharmaceutical Design The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Functional and Structural Alterations of Large Arteries: Methodological Issues
Current Pharmaceutical Design Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i
Current Vascular Pharmacology Investigating Key Genes in Type 2 Diabetes Mellitus via Combining mAP-KL and Mutual Information Network
Current Bioinformatics Does It Make Sense that Diabetes is Reciprocally Associated with Periodontal Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets The PD-1/PD-L1 Pathway in Human Pathology
Current Molecular Medicine Heterogeneity in the CD4 T Cell Compartment and the Variability of Neonatal Immune Responsiveness
Current Immunology Reviews (Discontinued) Endothelin-1 and Nitric Oxide in the Pathogenesis of Urinary Tract Disorders Secondary to Bladder Outlet Obstruction
Current Vascular Pharmacology Role of Free Radicals in Sepsis: Antioxidant Therapy
Current Pharmaceutical Design Therapeutic Agents for COVID-19: an Overview
Current Drug Therapy Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema
Current Pharmaceutical Design Vildagliptin Induces β-Cell Neogenesis and Improves the Lipid Profile in a Later Phase of Type 1 Diabetes
Current Pharmaceutical Biotechnology Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Induced Pluripotent Stem Cells and Their Potential for Basic and Clinical Sciences
Current Cardiology Reviews Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Systemic Delivery of Peptide Hormones Using Nasal Powders: Strategies and Future Perspectives
Drug Delivery Letters Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry